Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study

Abstract Background High-risk prostate cancer (PCa) is an extremely heterogeneous disease. A clear definition of prognostic subgroups is mandatory. Objective To develop a pretreatment prognostic model for PCa-specific survival (PCSS) in high-risk PCa based on combinations of unfavorable risk factors...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European urology 2015-01, Vol.67 (1), p.157-164
Hauptverfasser: Joniau, Steven, Briganti, Alberto, Gontero, Paolo, Gandaglia, Giorgio, Tosco, Lorenzo, Fieuws, Steffen, Tombal, Bertrand, Marchioro, Giansilvio, Walz, Jochen, Kneitz, Burkhard, Bader, Pia, Frohneberg, Detlef, Tizzani, Alessandro, Graefen, Markus, van Cangh, Paul, Karnes, R. Jeffrey, Montorsi, Francesco, Van Poppel, Hein, Spahn, Martin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 164
container_issue 1
container_start_page 157
container_title European urology
container_volume 67
creator Joniau, Steven
Briganti, Alberto
Gontero, Paolo
Gandaglia, Giorgio
Tosco, Lorenzo
Fieuws, Steffen
Tombal, Bertrand
Marchioro, Giansilvio
Walz, Jochen
Kneitz, Burkhard
Bader, Pia
Frohneberg, Detlef
Tizzani, Alessandro
Graefen, Markus
van Cangh, Paul
Karnes, R. Jeffrey
Montorsi, Francesco
Van Poppel, Hein
Spahn, Martin
description Abstract Background High-risk prostate cancer (PCa) is an extremely heterogeneous disease. A clear definition of prognostic subgroups is mandatory. Objective To develop a pretreatment prognostic model for PCa-specific survival (PCSS) in high-risk PCa based on combinations of unfavorable risk factors. Design, setting, and participants We conducted a retrospective multicenter cohort study including 1360 consecutive patients with high-risk PCa treated at eight European high-volume centers. Intervention Retropubic radical prostatectomy with pelvic lymphadenectomy. Outcome measurements and statistical analysis Two Cox multivariable regression models were constructed to predict PCSS as a function of dichotomization of clinical stage (20 ng/ml). The first “extended” model includes all seven possible combinations; the second “simplified” model includes three subgroups: a good prognosis subgroup (one single high-risk factor); an intermediate prognosis subgroup (PSA >20 ng/ml and stage cT3–4); and a poor prognosis subgroup (GS 8–10 in combination with at least one other high-risk factor). The predictive accuracy of the models was summarized and compared. Survival estimates and clinical and pathologic outcomes were compared between the three subgroups. Results and limitations The simplified model yielded an R2 of 33% with a 5-yr area under the curve (AUC) of 0.70 with no significant loss of predictive accuracy compared with the extended model (R2 : 34%; AUC: 0.71). The 5- and 10-yr PCSS rates were 98.7% and 95.4%, 96.5% and 88.3%, 88.8% and 79.7%, for the good, intermediate, and poor prognosis subgroups, respectively ( p = 0.0003). Overall survival, clinical progression-free survival, and histopathologic outcomes significantly worsened in a stepwise fashion from the good to the poor prognosis subgroups. Limitations of the study are the retrospective design and the long study period. Conclusions This study presents an intuitive and easy-to-use stratification of high-risk PCa into three prognostic subgroups. The model is useful for counseling and decision making in the pretreatment setting.
doi_str_mv 10.1016/j.eururo.2014.01.020
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1629956565</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0302283814000712</els_id><sourcerecordid>1629956565</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-daf54a5443a329ba3270e83d981a4468850d3740c7d0274267037e448e2f03e73</originalsourceid><addsrcrecordid>eNqFkU9v1DAQxS0EokvpN0AoRy4J4z-JEw5I1apQpCIqLT1brjNZvM3Gi-1U2m_fibZw4IIsjaXR84zf7zH2jkPFgTcfdxXOcY6hEsBVBbwCAS_Yirdalrpu4CVbgQRRila2Z-xNSjsAkHUnX7MzoVTbSNArNm5ytNkP3lENUxGG4tpvf5XRp4fiNoaUbcZibSeHsfBTDktzO1HfO2pn3IboMX0qLosr-swB7VR8n8fsSz-RJs_LVDsWmzz3x7fs1WDHhBfP9zm7-3L1c31d3vz4-m19eVM61epc9naola2VklaK7p6KBmxl37XcKtW0bQ291Aqc7kFoJRoNUiNZQjGARC3P2YfT3EMMv2dM2ex9cjiOdsIwJ8Mb0XV1Q4ek6iR15DVFHMwh-r2NR8PBLJzNzpw4m4WzAW6IMz17_7xhvt9j__fRH7Ak-HwSIPl89BhNch6JYu8jumz64P-34d8BbvQTxTQ-4BHTLsyRuJIXk4QBs1myXqLmimLWXMgnHIWliA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1629956565</pqid></control><display><type>article</type><title>Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Joniau, Steven ; Briganti, Alberto ; Gontero, Paolo ; Gandaglia, Giorgio ; Tosco, Lorenzo ; Fieuws, Steffen ; Tombal, Bertrand ; Marchioro, Giansilvio ; Walz, Jochen ; Kneitz, Burkhard ; Bader, Pia ; Frohneberg, Detlef ; Tizzani, Alessandro ; Graefen, Markus ; van Cangh, Paul ; Karnes, R. Jeffrey ; Montorsi, Francesco ; Van Poppel, Hein ; Spahn, Martin</creator><creatorcontrib>Joniau, Steven ; Briganti, Alberto ; Gontero, Paolo ; Gandaglia, Giorgio ; Tosco, Lorenzo ; Fieuws, Steffen ; Tombal, Bertrand ; Marchioro, Giansilvio ; Walz, Jochen ; Kneitz, Burkhard ; Bader, Pia ; Frohneberg, Detlef ; Tizzani, Alessandro ; Graefen, Markus ; van Cangh, Paul ; Karnes, R. Jeffrey ; Montorsi, Francesco ; Van Poppel, Hein ; Spahn, Martin ; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT)</creatorcontrib><description>Abstract Background High-risk prostate cancer (PCa) is an extremely heterogeneous disease. A clear definition of prognostic subgroups is mandatory. Objective To develop a pretreatment prognostic model for PCa-specific survival (PCSS) in high-risk PCa based on combinations of unfavorable risk factors. Design, setting, and participants We conducted a retrospective multicenter cohort study including 1360 consecutive patients with high-risk PCa treated at eight European high-volume centers. Intervention Retropubic radical prostatectomy with pelvic lymphadenectomy. Outcome measurements and statistical analysis Two Cox multivariable regression models were constructed to predict PCSS as a function of dichotomization of clinical stage (&lt;cT3 vs cT3–4), Gleason score (GS) (2–7 vs 8–10), and prostate-specific antigen (PSA; ≤20 ng/ml vs &gt;20 ng/ml). The first “extended” model includes all seven possible combinations; the second “simplified” model includes three subgroups: a good prognosis subgroup (one single high-risk factor); an intermediate prognosis subgroup (PSA &gt;20 ng/ml and stage cT3–4); and a poor prognosis subgroup (GS 8–10 in combination with at least one other high-risk factor). The predictive accuracy of the models was summarized and compared. Survival estimates and clinical and pathologic outcomes were compared between the three subgroups. Results and limitations The simplified model yielded an R2 of 33% with a 5-yr area under the curve (AUC) of 0.70 with no significant loss of predictive accuracy compared with the extended model (R2 : 34%; AUC: 0.71). The 5- and 10-yr PCSS rates were 98.7% and 95.4%, 96.5% and 88.3%, 88.8% and 79.7%, for the good, intermediate, and poor prognosis subgroups, respectively ( p = 0.0003). Overall survival, clinical progression-free survival, and histopathologic outcomes significantly worsened in a stepwise fashion from the good to the poor prognosis subgroups. Limitations of the study are the retrospective design and the long study period. Conclusions This study presents an intuitive and easy-to-use stratification of high-risk PCa into three prognostic subgroups. The model is useful for counseling and decision making in the pretreatment setting.</description><identifier>ISSN: 0302-2838</identifier><identifier>EISSN: 1873-7560</identifier><identifier>DOI: 10.1016/j.eururo.2014.01.020</identifier><identifier>PMID: 24486307</identifier><language>eng</language><publisher>Switzerland: Elsevier B.V</publisher><subject>Aged ; Area Under Curve ; Disease-Free Survival ; Europe ; High-risk prostate cancer ; Humans ; Locally advanced prostate cancer ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Predictive Value of Tests ; Proportional Hazards Models ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - classification ; Prostatic Neoplasms - pathology ; Retrospective Studies ; Risk Assessment - methods ; Risk Factors ; Risk groups ; Risk stratification ; Survival Rate ; Urology</subject><ispartof>European urology, 2015-01, Vol.67 (1), p.157-164</ispartof><rights>European Association of Urology</rights><rights>2014 European Association of Urology</rights><rights>Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-daf54a5443a329ba3270e83d981a4468850d3740c7d0274267037e448e2f03e73</citedby><cites>FETCH-LOGICAL-c487t-daf54a5443a329ba3270e83d981a4468850d3740c7d0274267037e448e2f03e73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0302283814000712$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24486307$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Joniau, Steven</creatorcontrib><creatorcontrib>Briganti, Alberto</creatorcontrib><creatorcontrib>Gontero, Paolo</creatorcontrib><creatorcontrib>Gandaglia, Giorgio</creatorcontrib><creatorcontrib>Tosco, Lorenzo</creatorcontrib><creatorcontrib>Fieuws, Steffen</creatorcontrib><creatorcontrib>Tombal, Bertrand</creatorcontrib><creatorcontrib>Marchioro, Giansilvio</creatorcontrib><creatorcontrib>Walz, Jochen</creatorcontrib><creatorcontrib>Kneitz, Burkhard</creatorcontrib><creatorcontrib>Bader, Pia</creatorcontrib><creatorcontrib>Frohneberg, Detlef</creatorcontrib><creatorcontrib>Tizzani, Alessandro</creatorcontrib><creatorcontrib>Graefen, Markus</creatorcontrib><creatorcontrib>van Cangh, Paul</creatorcontrib><creatorcontrib>Karnes, R. Jeffrey</creatorcontrib><creatorcontrib>Montorsi, Francesco</creatorcontrib><creatorcontrib>Van Poppel, Hein</creatorcontrib><creatorcontrib>Spahn, Martin</creatorcontrib><creatorcontrib>European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT)</creatorcontrib><title>Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study</title><title>European urology</title><addtitle>Eur Urol</addtitle><description>Abstract Background High-risk prostate cancer (PCa) is an extremely heterogeneous disease. A clear definition of prognostic subgroups is mandatory. Objective To develop a pretreatment prognostic model for PCa-specific survival (PCSS) in high-risk PCa based on combinations of unfavorable risk factors. Design, setting, and participants We conducted a retrospective multicenter cohort study including 1360 consecutive patients with high-risk PCa treated at eight European high-volume centers. Intervention Retropubic radical prostatectomy with pelvic lymphadenectomy. Outcome measurements and statistical analysis Two Cox multivariable regression models were constructed to predict PCSS as a function of dichotomization of clinical stage (&lt;cT3 vs cT3–4), Gleason score (GS) (2–7 vs 8–10), and prostate-specific antigen (PSA; ≤20 ng/ml vs &gt;20 ng/ml). The first “extended” model includes all seven possible combinations; the second “simplified” model includes three subgroups: a good prognosis subgroup (one single high-risk factor); an intermediate prognosis subgroup (PSA &gt;20 ng/ml and stage cT3–4); and a poor prognosis subgroup (GS 8–10 in combination with at least one other high-risk factor). The predictive accuracy of the models was summarized and compared. Survival estimates and clinical and pathologic outcomes were compared between the three subgroups. Results and limitations The simplified model yielded an R2 of 33% with a 5-yr area under the curve (AUC) of 0.70 with no significant loss of predictive accuracy compared with the extended model (R2 : 34%; AUC: 0.71). The 5- and 10-yr PCSS rates were 98.7% and 95.4%, 96.5% and 88.3%, 88.8% and 79.7%, for the good, intermediate, and poor prognosis subgroups, respectively ( p = 0.0003). Overall survival, clinical progression-free survival, and histopathologic outcomes significantly worsened in a stepwise fashion from the good to the poor prognosis subgroups. Limitations of the study are the retrospective design and the long study period. Conclusions This study presents an intuitive and easy-to-use stratification of high-risk PCa into three prognostic subgroups. The model is useful for counseling and decision making in the pretreatment setting.</description><subject>Aged</subject><subject>Area Under Curve</subject><subject>Disease-Free Survival</subject><subject>Europe</subject><subject>High-risk prostate cancer</subject><subject>Humans</subject><subject>Locally advanced prostate cancer</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Staging</subject><subject>Predictive Value of Tests</subject><subject>Proportional Hazards Models</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - classification</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Retrospective Studies</subject><subject>Risk Assessment - methods</subject><subject>Risk Factors</subject><subject>Risk groups</subject><subject>Risk stratification</subject><subject>Survival Rate</subject><subject>Urology</subject><issn>0302-2838</issn><issn>1873-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9v1DAQxS0EokvpN0AoRy4J4z-JEw5I1apQpCIqLT1brjNZvM3Gi-1U2m_fibZw4IIsjaXR84zf7zH2jkPFgTcfdxXOcY6hEsBVBbwCAS_Yirdalrpu4CVbgQRRila2Z-xNSjsAkHUnX7MzoVTbSNArNm5ytNkP3lENUxGG4tpvf5XRp4fiNoaUbcZibSeHsfBTDktzO1HfO2pn3IboMX0qLosr-swB7VR8n8fsSz-RJs_LVDsWmzz3x7fs1WDHhBfP9zm7-3L1c31d3vz4-m19eVM61epc9naola2VklaK7p6KBmxl37XcKtW0bQ291Aqc7kFoJRoNUiNZQjGARC3P2YfT3EMMv2dM2ex9cjiOdsIwJ8Mb0XV1Q4ek6iR15DVFHMwh-r2NR8PBLJzNzpw4m4WzAW6IMz17_7xhvt9j__fRH7Ak-HwSIPl89BhNch6JYu8jumz64P-34d8BbvQTxTQ-4BHTLsyRuJIXk4QBs1myXqLmimLWXMgnHIWliA</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Joniau, Steven</creator><creator>Briganti, Alberto</creator><creator>Gontero, Paolo</creator><creator>Gandaglia, Giorgio</creator><creator>Tosco, Lorenzo</creator><creator>Fieuws, Steffen</creator><creator>Tombal, Bertrand</creator><creator>Marchioro, Giansilvio</creator><creator>Walz, Jochen</creator><creator>Kneitz, Burkhard</creator><creator>Bader, Pia</creator><creator>Frohneberg, Detlef</creator><creator>Tizzani, Alessandro</creator><creator>Graefen, Markus</creator><creator>van Cangh, Paul</creator><creator>Karnes, R. Jeffrey</creator><creator>Montorsi, Francesco</creator><creator>Van Poppel, Hein</creator><creator>Spahn, Martin</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150101</creationdate><title>Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study</title><author>Joniau, Steven ; Briganti, Alberto ; Gontero, Paolo ; Gandaglia, Giorgio ; Tosco, Lorenzo ; Fieuws, Steffen ; Tombal, Bertrand ; Marchioro, Giansilvio ; Walz, Jochen ; Kneitz, Burkhard ; Bader, Pia ; Frohneberg, Detlef ; Tizzani, Alessandro ; Graefen, Markus ; van Cangh, Paul ; Karnes, R. Jeffrey ; Montorsi, Francesco ; Van Poppel, Hein ; Spahn, Martin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-daf54a5443a329ba3270e83d981a4468850d3740c7d0274267037e448e2f03e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Area Under Curve</topic><topic>Disease-Free Survival</topic><topic>Europe</topic><topic>High-risk prostate cancer</topic><topic>Humans</topic><topic>Locally advanced prostate cancer</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Staging</topic><topic>Predictive Value of Tests</topic><topic>Proportional Hazards Models</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - classification</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Retrospective Studies</topic><topic>Risk Assessment - methods</topic><topic>Risk Factors</topic><topic>Risk groups</topic><topic>Risk stratification</topic><topic>Survival Rate</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Joniau, Steven</creatorcontrib><creatorcontrib>Briganti, Alberto</creatorcontrib><creatorcontrib>Gontero, Paolo</creatorcontrib><creatorcontrib>Gandaglia, Giorgio</creatorcontrib><creatorcontrib>Tosco, Lorenzo</creatorcontrib><creatorcontrib>Fieuws, Steffen</creatorcontrib><creatorcontrib>Tombal, Bertrand</creatorcontrib><creatorcontrib>Marchioro, Giansilvio</creatorcontrib><creatorcontrib>Walz, Jochen</creatorcontrib><creatorcontrib>Kneitz, Burkhard</creatorcontrib><creatorcontrib>Bader, Pia</creatorcontrib><creatorcontrib>Frohneberg, Detlef</creatorcontrib><creatorcontrib>Tizzani, Alessandro</creatorcontrib><creatorcontrib>Graefen, Markus</creatorcontrib><creatorcontrib>van Cangh, Paul</creatorcontrib><creatorcontrib>Karnes, R. Jeffrey</creatorcontrib><creatorcontrib>Montorsi, Francesco</creatorcontrib><creatorcontrib>Van Poppel, Hein</creatorcontrib><creatorcontrib>Spahn, Martin</creatorcontrib><creatorcontrib>European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Joniau, Steven</au><au>Briganti, Alberto</au><au>Gontero, Paolo</au><au>Gandaglia, Giorgio</au><au>Tosco, Lorenzo</au><au>Fieuws, Steffen</au><au>Tombal, Bertrand</au><au>Marchioro, Giansilvio</au><au>Walz, Jochen</au><au>Kneitz, Burkhard</au><au>Bader, Pia</au><au>Frohneberg, Detlef</au><au>Tizzani, Alessandro</au><au>Graefen, Markus</au><au>van Cangh, Paul</au><au>Karnes, R. Jeffrey</au><au>Montorsi, Francesco</au><au>Van Poppel, Hein</au><au>Spahn, Martin</au><aucorp>European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study</atitle><jtitle>European urology</jtitle><addtitle>Eur Urol</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>67</volume><issue>1</issue><spage>157</spage><epage>164</epage><pages>157-164</pages><issn>0302-2838</issn><eissn>1873-7560</eissn><abstract>Abstract Background High-risk prostate cancer (PCa) is an extremely heterogeneous disease. A clear definition of prognostic subgroups is mandatory. Objective To develop a pretreatment prognostic model for PCa-specific survival (PCSS) in high-risk PCa based on combinations of unfavorable risk factors. Design, setting, and participants We conducted a retrospective multicenter cohort study including 1360 consecutive patients with high-risk PCa treated at eight European high-volume centers. Intervention Retropubic radical prostatectomy with pelvic lymphadenectomy. Outcome measurements and statistical analysis Two Cox multivariable regression models were constructed to predict PCSS as a function of dichotomization of clinical stage (&lt;cT3 vs cT3–4), Gleason score (GS) (2–7 vs 8–10), and prostate-specific antigen (PSA; ≤20 ng/ml vs &gt;20 ng/ml). The first “extended” model includes all seven possible combinations; the second “simplified” model includes three subgroups: a good prognosis subgroup (one single high-risk factor); an intermediate prognosis subgroup (PSA &gt;20 ng/ml and stage cT3–4); and a poor prognosis subgroup (GS 8–10 in combination with at least one other high-risk factor). The predictive accuracy of the models was summarized and compared. Survival estimates and clinical and pathologic outcomes were compared between the three subgroups. Results and limitations The simplified model yielded an R2 of 33% with a 5-yr area under the curve (AUC) of 0.70 with no significant loss of predictive accuracy compared with the extended model (R2 : 34%; AUC: 0.71). The 5- and 10-yr PCSS rates were 98.7% and 95.4%, 96.5% and 88.3%, 88.8% and 79.7%, for the good, intermediate, and poor prognosis subgroups, respectively ( p = 0.0003). Overall survival, clinical progression-free survival, and histopathologic outcomes significantly worsened in a stepwise fashion from the good to the poor prognosis subgroups. Limitations of the study are the retrospective design and the long study period. Conclusions This study presents an intuitive and easy-to-use stratification of high-risk PCa into three prognostic subgroups. The model is useful for counseling and decision making in the pretreatment setting.</abstract><cop>Switzerland</cop><pub>Elsevier B.V</pub><pmid>24486307</pmid><doi>10.1016/j.eururo.2014.01.020</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0302-2838
ispartof European urology, 2015-01, Vol.67 (1), p.157-164
issn 0302-2838
1873-7560
language eng
recordid cdi_proquest_miscellaneous_1629956565
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Aged
Area Under Curve
Disease-Free Survival
Europe
High-risk prostate cancer
Humans
Locally advanced prostate cancer
Male
Middle Aged
Neoplasm Grading
Neoplasm Staging
Predictive Value of Tests
Proportional Hazards Models
Prostate-Specific Antigen - blood
Prostatic Neoplasms - blood
Prostatic Neoplasms - classification
Prostatic Neoplasms - pathology
Retrospective Studies
Risk Assessment - methods
Risk Factors
Risk groups
Risk stratification
Survival Rate
Urology
title Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T08%3A30%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stratification%20of%20High-risk%20Prostate%20Cancer%20into%20Prognostic%20Categories:%20A%20European%20Multi-institutional%20Study&rft.jtitle=European%20urology&rft.au=Joniau,%20Steven&rft.aucorp=European%20Multicenter%20Prostate%20Cancer%20Clinical%20and%20Translational%20Research%20Group%20(EMPaCT)&rft.date=2015-01-01&rft.volume=67&rft.issue=1&rft.spage=157&rft.epage=164&rft.pages=157-164&rft.issn=0302-2838&rft.eissn=1873-7560&rft_id=info:doi/10.1016/j.eururo.2014.01.020&rft_dat=%3Cproquest_cross%3E1629956565%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1629956565&rft_id=info:pmid/24486307&rft_els_id=1_s2_0_S0302283814000712&rfr_iscdi=true